TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18192779
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy of a limited duration
Study: 12911201
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 microg x kg(‐1)) and propofol (1.8 mg x kg(‐1))
Study: 12911201
Drug: N2O/sevoflurane (4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: N2O/sevoflurane (4% sevoflurane in N2O at 41 x min(‐1) and oxygen at 21 min(‐1)) and propofol (1.8 mg x kg(‐1))
Study: 9315416
Drug: Deep injection
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep injection of local anesthetics (n = 31), paracervical block involving four injections approximately 3 cm deep
Study: 9315416
Drug: Regular injection
Normalized name: diluent,insulin lispro,regular INJECTION VIAL (ML)
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular injection of local anesthetics (n = 35), paracervical block involving four injections approximately 1.5 cm deep
Study: 9315416
Drug: Deep injection
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep injection of local anesthetics (n = 31)
Study: 9315416
Drug: Regular injection
Normalized name: diluent,insulin lispro,regular INJECTION VIAL (ML)
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular injection of local anesthetics (n = 35)
Study: 8436146
Drug: Diclofenac 50
Normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 50 mg t.i.d. as additive treatment to morphine
Study: 3014855
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (500 mg elemental calcium)
Study: 3014855
Drug: Hydroxyapatite (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyapatite (500 mg elemental calcium)
Study: 27574730
Drug: Conditioning procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning procedure on pain tolerance with belief in analgesic treatment (Experiment 1)
Study: 23039403
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg once a day
Study: 22726241
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg) 0.4, 0.6 and/or 0.8 U/kg once daily for two 6-day periods
Study: 8941691
Drug: Aspirin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 100 mg daily, starting from the 3rd postoperative day (14 patients)
Study: 3533127
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg biphasic release formulation twice daily)
Study: 27513404
Drug: Intramuscular diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular diclofenac sodium 75 mg
Study: 27513404
Drug: Rectal diclofenac
Normalized name: diclofenac Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal diclofenac sodium 100 mg
Study: 24864182
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 g/1.73 m2 per day for 3 days)
Study: 16316558
Drug: Cilostazol 200
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200 mg/d for 6 months
Study: 16316558
Drug: Ticlopidine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 500 mg/d for 1 month
Study: 12854625
Drug: Metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose inhaler with spacer
Study: 10584041
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (5 g/MJ, 19% of total energy)
Study: 10584041
Drug: Sunflower oil
Normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower oil (5 g/MJ, 19% of total energy)
Study: 10584041
Drug: Rapeseed oil
Normalized name: Rapeseed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapeseed oil (5 g/MJ, 19% of total energy)
Study: 8651516
Drug: Manual disinfection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual disinfection procedures using five disinfectants (two 2% alkaline glutaraldehyde preparations, 3.2% alkaline glutaraldehyde, 75 ppm iodophor, and 0.5% glutaraldehyde-0.03% phenolic)
Study: 2009789
Drug: Aerosolized BN52021
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosolized BN52021 (PAF antagonist)
Study: 7010650
Drug: 4% HSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% HSA in Ringer's lactate solution (RL) resuscitation
Study: 7010650
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution (RL) resuscitation
Study: 27914846
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg triamcinolone acetonide injection
Study: 27914846
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg triamcinolone acetonide injection
Study: 24092240
Drug: Western music
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western music therapy
Study: 19756348
Drug: PTH(1-84) 100
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH(1-84) 100 mcg
Study: 19756348
Drug: PTH(1-34) 20
Normalized name: PTH
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH(1-34) 20 mcg
Study: 15118187
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (40 g protein/d)
Study: 15118187
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (40 g protein/d)
Study: 9498442
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated chikungunya virus (CHIKV) vaccine
Study: 9498442
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated VEEV vaccine
Study: 7919944
Drug: Mirtazapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (15 mg to 50 mg)
Study: 2838231
Drug: Ketotifen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (2 X 1 mg/day for 1 week)
Study: 25376930
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch monotherapy
Study: 25376930
Drug: Memantine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine plus rivastigmine transdermal patch therapy
Study: 25376930
Drug: Rivastigmine patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch or memantine add‐on therapy
Study: 21414183
Drug: Myoinositol supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myoinositol supplementation (4 g daily) plus folic acid (400 μg daily)
Study: 21414183
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid only (400 μg daily)
Study: 17046467
Drug: No antimalarial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antimalarial drugs
Study: 12670066
Drug: Hybrid composite
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid composite (Tetric) plus adhesive bonding agent (Syntac Classic)
Study: 12670066
Drug: Compomer (Dyract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compomer (Dyract AP) plus adhesive bonding agent (Prime & Bond NT)
Study: 11074747
Drug: Once-daily enoxaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily enoxaparin
Study: 8753708
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of cephapirin sodium and gentamicin for three days
Study: 8753708
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of ciprofloxacin for three days
Study: 3574639
Drug: Flupentixol 2
Normalized name: flupenthixol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol 2 mg/day
Study: 3574639
Drug: Flupentixol 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol 1 mg/day
Study: 3574639
Drug: Flupentixol 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol 0 mg/day (control)
Study: 3574639
Drug: Flupentixol (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol (0, 1, and 2 mg)
Study: 29943163
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg for 8 weeks
Study: 29799875
Drug: Tenofovir-containing vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir-containing vaginal gel or insert
Study: 29799875
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo products (vaginal gel or insert)
Study: 22745573
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine iv bolus
Study: 22745573
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg iv paracetamol infusion
Study: 17126520
Drug: Percutaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous treatment with expanded polytetrafluoroethylene (ePTFE)/nitinol self‐expanding stent grafts
Study: 10320254
Drug: Venoarterial pedicle
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venoarterial pedicle preparation (group B)
Study: 25159623
Drug: Fast atazanavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast atazanavir clearance (≥9 L/h) in females
Study: 25159623
Drug: Slow atazanavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow atazanavir clearance (<7 L/h) in males
Study: 25159623
Drug: Middle atazanavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle atazanavir clearance (7 to <9 L/h)
Study: 9717867
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy for weeks 1 to 16
Study: 9717867
Drug: Fluvoxamine for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine for weeks 1 to 16 plus cognitive therapy in weeks 9 to 16
Study: 7656956
Drug: Ambulatory oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory oxygen at 2 L.min‐1
Study: 2663737
Drug: Cephradine 2
Normalized name: cephradine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephradine 2 g intravenously
Study: 2663737
Drug: Cefuroxime 1.5
Normalized name: cefuroxime 1.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1.5 g intravenously
Study: 205226
Drug: digoxin/silica matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: digoxin/silica matrix tablets (Digacin)
Study: 205226
Drug: digoxin/silica matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: digoxin/silica matrix in capsule form
Study: 205226
Drug: digoxin/silica matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: digoxin/silica matrix formulations (in vitro)
Study: 205226
Drug: conventional tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional tablets from digoxin-lactose trituration (in vitro)
Study: 28654304
Drug: Active continuous
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active continuous diffusion of oxygen (CDO) therapy
Study: 28654304
Drug: Sham device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham device providing moist wound therapy (MWT)
Study: 25453567
Drug: Chlorhexidine (CHX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine (CHX), 2% CHX gel
Study: 25453567
Drug: Ca(OH)2/CHX, Ca(OH)2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca(OH)2/CHX, Ca(OH)2 + 2% CHX gel
Study: 21806906
Drug: Freeze dried
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze dried powdered combination of Lactobacillus rhamnosus and Bifidobacterium species
Study: 21806906
Drug: Freeze dried
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze dried powdered preparation of Bacillus coagulans
Study: 11336156
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d. over 5 days
Study: 9160036
Drug: Brow treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brow treatment (B)
Study: 9160036
Drug: Inner orbital
Normalized name: isosulfan blue inner salt
DrugBank: Isosulfan blue (DB09136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inner orbital treatment (IO)
Study: 9160036
Drug: Outer orbital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outer orbital treatment (OO)
Study: 31373696
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered glucocorticosteroids preoperatively
Study: 31373696
Drug: Endoscopic sinus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic sinus surgery (ESS) without preoperative steroids
Study: 31217344
Drug: Palbociclib +
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib + letrozole (palbociclib: 125 mg daily; 3 weeks on/1 week off; letrozole: 2.5 mg daily continuously)
Study: 31217344
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + letrozole (letrozole: 2.5 mg daily continuously)
Study: 14704262
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (0.05 mg/d) plus progestin (2.5 mg/d; n = 31)
Study: 14704262
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (0.625 mg/d) plus progestin (2.5 mg/d; n = 30)
Study: 9220037
Drug: Nifedipine coat-core
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine coat-core (CC)
Study: 29234884
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy combined with steroid injection (Group 1)
Study: 29234884
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection (Group 2)
Study: 26909885
Drug: Gaviscon Advance
Normalized name: Gaviscon
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaviscon Advance 10 mL four times a day
Study: 24982236
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with DFX 30 mg/kg
Study: 24982236
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with DFP 80 mg/kg/day
Study: 24982236
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with DFX 30 mg/kg and DFP 40 mg/kg
Study: 24982236
Drug: Concurrent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent therapy with DFX 30 mg/kg and DFP 80 mg/kg
Study: 22156009
Drug: Bilateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral injection (C: 6 mL/s; D: 8 mL/s)
Study: 22156009
Drug: Unilateral injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral injection (A: 4 mL/s; B: 6 mL/s)
Study: 20728299
Drug: B-MAT (buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-MAT (buprenorphine medication-assisted treatment)
Study: 19167585
Drug: Prefilled insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prefilled insulin delivery device (NovoMix 30 FlexPen)
Study: 19167585
Drug: Reusable insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reusable insulin delivery device (HumaPen Luxura)
Study: 19167585
Drug: Injection time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection time excluding cartridge insertion for HL device
Study: 11174477
Drug: Estradiol plus
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol plus sequential norethindrone acetate
Study: 30957447
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (surround needling + acupoint injection)
Study: 28416501
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU, twice daily for 2 weeks)
Study: 28416501
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 2 weeks)
Study: 22972566
Drug: Ketofol (1:1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketofol (1:1 mixture of 5 mg/ml ketamine and 5 mg/ml propofol)
Study: 22972566
Drug: Propofol 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.15 ml/kg
Study: 12949687
Drug: Epigam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epigam (1 tablet, 6 times a day)
Study: 12949687
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg, 2 times a day)
Study: 9055055
Drug: Slow-release gemfibrozil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release gemfibrozil, 1200 mg once daily
Study: 25236993
Drug: Desmopressin orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin orally disintegrating tablet
Study: 16988138
Drug: Fortified milk
Normalized name: Fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified milk (FM) with 5.8 mg iron as ferrous gluconate, 5.28 mg zinc as zinc oxide, and 48 mg ascorbic acid per 400 mL
Study: 16988138
Drug: Nonfortified milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonfortified milk (NFM) with 0.2 mg iron, 1.9 mg zinc, and 6.8 mg ascorbic acid per 400 mL
Study: 12729425
Drug: 10-mg warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg warfarin initiation nomogram
Study: 12729425
Drug: 5-mg warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg warfarin initiation nomogram
Study: 10979111
Drug: Celecoxib, 400
Normalized name: Celecoxib, 400 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib, 400 mg twice per day (n = 3987)
Study: 10979111
Drug: NSAIDs (ibuprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (ibuprofen, 800 mg 3 times per day; n = 1985) or diclofenac, 75 mg twice per day (n = 1996)
Study: 29943384
Drug: Herbal vaginal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal vaginal suppository containing 10% myrtle aqueous extract and 0.5% myrtle essential oil, prescribed for 3 months (20 suppositories at each menstrual cycle)
Study: 29943384
Drug: Placebo vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal suppository, prescribed for 3 months (20 suppositories at each menstrual cycle)
Study: 29943384
Drug: Herbal vaginal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal vaginal suppository containing 10% myrtle aqueous extract and 0.5% myrtle essential oil
Study: 26873229
Drug: Daclizumab HYP
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab HYP (150 mg SC every 4 weeks)
Study: 26873229
Drug: Daclizumab HYP
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab HYP (100-300 mg SC)
Study: 12195876
Drug: Lamivudine and
Normalized name: lamivudine and abacavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine and famciclovir combination therapy
Study: 12195876
Drug: Lamivudine and
Normalized name: lamivudine and abacavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine and famciclovir combination therapy with IFN-alpha 2b
Study: 10096821
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite avoidance therapy (including allergen-impermeable encasement of mattresses and other strategies)
Study: 7534055
Drug: Control (non-heparin-coated)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (non-heparin-coated) cardiopulmonary bypass
Study: 678387
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg long‐acting capsule formulation (LA)
Study: 678387
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg twice a day regimen (CP80)
Study: 30309970
Drug: Sequential DMARD-monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential DMARD-monotherapy (sulfasalazine or methotrexate)
Study: 30309970
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy MTX + 6 weeks prednisolone
Study: 30309970
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy MTX + etanercept
Study: 25710801
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer carbonate (SC) 1600 mg, three times a day
Study: 21849147
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Mailuo Shutong Granule + Hirudoid cream)
Study: 19433997
Drug: Team care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Team care with proactive clinical pharmacist services (medication history, patient-care round participation, resolution of drug-related issues, discharge counseling)
Study: 14616458
Drug: oxybutynin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxybutynin IR 3 mg three times daily
Study: 1359166
Drug: Timing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing with priming (0.005 mg.kg‐1 vecuronium as priming doses followed by 0.15 mg.kg‐1 vecuronium)
Study: 1359166
Drug: Timing (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing (0.15 mg.kg‐1 vecuronium)
Study: 30184110
Drug: JNJ‐9375 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐9375 (250 μg/mL)